Evaluate L-carnitine treatment response in moderate cancer fatigue patients

Evaluate L-carnitine treatment response in moderate cancer fatigue patients - Treatment of cancer-related fatigue

Status

Active, not recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400088445

Enrollment

Unknown

Registered

2024-08-19

Start date

2024-09-01

Completion date

Unknown

Last updated

2024-08-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer, Neoplasm

Interventions

intervention group:During the experiment, each subject received intravenous infusion of L-carnitine, three times a week, 1g each time. After two weeks of treatment, assess whether there has been any i

Eligibility

Sex/Gender

All

Age

20 Years to 85 Years

Inclusion criteria

Inclusion criteria: Patients with moderate to severe cancer-related fatigue, aged 20 to 85 years, with a fatigue score of 4 or higher on the scale, who are conscious and able to complete the questionnaire.

Exclusion criteria

Exclusion criteria: 1. Patients who are unable or unwilling to receive intravenous injections. 2. Individuals allergic to L-carnitine. 3. Patients with a history of seizures. 4. Severe depression. 5. Pregnant or breastfeeding patients.

Design outcomes

Primary

Measure	Time frame
BFI- Taiwan Form;Patient Generated-Subjective Global Assessment;	—

Countries

China

Contacts

Public ContactKa-Ee Ling

Tainan Sin-Lau Hospital

d4039@sinlau.org.tw+886 6 274 8316

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026